Abstract
Fluorouracil (5-FU) is widely used in the treatment of colorectal cancer. Methylenetetrahydrofolate reductase (MTHFR) may play a central role in the action of 5-FU, an inhibitor of thymidylate synthase, by converting 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. The aim of this study was to ascertain whether two polymorphisms in the MTHFR gene (677C>T and 1298 A>C) could be used as genomic predictors of clinical response to fluoropyrimidine-based chemotherapy (in combination with irinotecan or oxaliplatin). Ninety-four patients diagnosed with metastatic colorectal cancer and undergoing 5-FU-containing chemotherapy as a first line treatment were studied. The results suggest that the MTHFR genotype cannot be considered as an independent factor of outcome in colorectal cancer patients under 5-FU-based chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R (2003) Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9:1611–1615
Danenberg PV (1977) Thymidylate synthetase: a target enzyme in cancer chemotherapy. Biochim Biophys Acta 473:73–92
Etienne MC, Llc K, Formento JL, Laurent-Puig P, Formento P, Cheradame S, Fischel JL, Milano G (2004) Thymidylate synthase and methylenetetradydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. Br J Cancer 90:526–534
Etienne MC, Formento JL, Chazal M, Francoual M, Magné N, Formento P, Bourgeon A, Seitz JF, Delpero JR, Letoublon C, Pezet D, Milano G, (2004) Pharmacogenetics 14:785–792
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen RA (1995) Candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 10:111–113
Goyette P, Pai A, Milos R, Frosst P, Tran P, Chen Z, Chan M, Rozen R (1998) Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mammalian Genome 9:652–656
Gutierrez JI, Perez F, Calvo T, Tamparillas M, Gracia J (2003) Implicación de los polimorfismos C677T y A1298C del gen MTHFR en el desarrollo de los defectos del tubo neural en la población española. Med Clin (Barc) 120:441–445
Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J (2005) Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23:1365–1369
Kiffmeyer WR, Langer E, Davies S, Envall J, Robison L, Ross J (2004) Genetic polymorphisms in the Hmong population. Cancer 100:411–417
Longley DB, Harkin DP, Johnston PG, (2003) 5-Fluorouracil mechanisms of action and clinical strategies. Nat Rev Cancer 3:3330–338
Marcuello E, Altés A, Del Rio E, César A, Menoyo A, Baiget M (2004) Single nucleotide polymorphism in the 3’ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 112:733–737
Martinez-Frias ML, Bermejo E, Rodriguez-Pinilla E, Scala I, Andria G, Botto L, and ECEMC group (2004) Frecuencia de la mutacion 677C-T del gen de la metilentetrahidrofolato reductasa en una muestra de 652 recien nacidos de toda España. Med Clin (Barc) 122:361–364
Miller SA, Dykes DD, Polesky H (1989) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215
Sekhon J, Pereira P, Sabbaghian N, Schievella AR, Rozen R (2002) Antisense inhibition of methylenetetrahydrofolate reductase reduces survival of methionine-dependent tumour lines. Br Jcancer 87:225–230
Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI (2004) Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-Fluorouracil and Methotrexate. J Natl Cancer Inst 96:134–144
Stankova J, Shang J, Rozen R (2005) Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell survival In vitro and tumor growth in vivo. Clinical Cancer Research 11:2047–2052
Van der Put N, Gabreëls F, Stevens E, Smeitink J, Trijbels F, Eskes T, van den Heuvel L, Blom H (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects? Am J Hum Genet 62:1044–1051
Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Redlund M, Stoll C, Alembik Y, Dott B, Czeizel AE, Gelman-Kohan Z, Scarano G, Bianca S, Ettore G, Tenconi R, Bellato S, Scala I, Mutchinick OM, Lopez MA, de Walle H, Hofstra R, Joutchenko L, Kavteladze L, Bermejo E, Martinez-Frias ML, Gallagher M, Erickson JD, Vollset SE, Mastroiacovo P, Andria G, Botto LD (2003) Geographical and ethnic variation of the 677C>T allele of MTHFR: findings from over 7000 newborns from 16 areas worldwide. J Med Genet 40:619–625
World Health Organization: Handbook for Reporting Results of Cancer Treatment. Publication n° 48. Geneva, Switzerland: World Health Organization; 1979)
Acknowledgements
This work was supported by grant SAF2001-1055 from the Spanish Ministry of Science and Technology.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marcuello, E., Altés, A., Menoyo, A. et al. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?. Cancer Chemother Pharmacol 57, 835–840 (2006). https://doi.org/10.1007/s00280-005-0089-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-005-0089-1